Efficacy of XELOX regimen combined with bevacizumab for treatment of patients with advanced colorectal cancer and its clinical significances
10.3760/cma.j.cn115355-20240118-00039
- VernacularTitle:XELOX方案联合贝伐珠单抗治疗晚期结直肠癌的效果及其临床意义
- Author:
Li LI
1
;
Guangyu GAO
;
Zhaoyi FU
;
Min ZHANG
Author Information
1. 苏州高新区人民医院肿瘤科，苏州 215000
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Drug therapy, combination;
Molecular targeted therapy
- From:
Cancer Research and Clinic
2024;36(12):898-902
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of XELOX regimen combined with bevacizumab for treatment of patients with advanced colorectal cancer and its clinical significances.Methods:A prospective randomized controlled study was conducted. Seventy-eight patients with advanced colorectal cancer who received treatment at People's Hospital of Suzhou New District and the Second Affiliated Hospital of Soochow University from February 2019 to November 2020 were selected. According to the random number table method, they were divided into the treatment group (40 cases) and the control group (38 cases). The treatment group received bevacizumab combined with XELOX regimen, while the control group only received XELOX regimen chemotherapy. The short-term efficacy, levels of tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and carbohydrate antigen 199 (CA199)], levels of cytokines [interleukin-1 (IL-1), interleukin-6 (IL-6), erythrocyte sedimentation rate (ESR), and albumin (ALB)], and incidence of adverse reactions were compared between the two groups. Kaplan-Meier method was used to analyze the overall survival (OS) of the two groups, and log-rank test was performed.Results:In 78 patients with colorectal cancer, there were 47 males and 31 females; the age was (59±16) years old. The overall response rate of the treatment group was higher than that of the control group [55.00% (22/40) vs. 26.31% (10/38)], and the difference was statistically significant ( χ2 = 6.63, P < 0.05). There were no statistically significant differences in the levels of tumor markers and cytokines between the two groups before treatment (all P > 0.05). After treatment, the levels of CA199, CA125, CEA, IL-1, IL-6, and ESR in the treatment group were lower than those in the control group [CA199: (22±4) U/ml vs. (27± 4) U/ml, CA125: (35±3) U/ml vs. (37±4) U/ml, CEA: (4.4±0.7) ng/ml vs. (5.0±1.0) ng/ml, IL-1: (29± 4) pg/ml vs. (34±4) pg/ml, IL-6: (14.0±2.3) ng/L vs. (15.3±2.5) ng/L, ESR: (9.2±2.0) mm/1 h vs. (13.6±2.1) mm/1 h], ALB level was higher than that in the control group [(34.3±1.5) g/L vs. (29.8±1.4) g/L], and the differences were statistically significant (all P < 0.05). The difference in the incidence of adverse reactions between the two groups was not statistically significant ( P > 0.05). As of the end of follow-up, the OS of the treatment group was better than that of the control group, and the difference was statistically significant ( P = 0.004). Conclusions:The combination of XELOX regimen and bevacizumab targeted therapy can reduce the levels of tumor markers and inflammatory cytokines in patients with advanced colorectal cancer, and improve their prognosis with high safety.
